stockrow
Monday 9 November 2026
Export ACIU’s income statement to Excel — free account
AC Immune
ACIUAC Immune’s revenue for fiscal 2025 (year ended December 2025) was $4.3 million, down 86.1% from fiscal 2024.
- Revenue
- +152.3%
- EPS
- +36.0%
- Free cash flow
- +4.66%
Quarter to September 2026, against a year earlier
2.23
0.12
+5.69%
Follow ACIU
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | — | 0.00 |
P/S ratio |
73.36 | 58.49 | — | 25.01 | |
P/FCF ratio |
0.00 | 0.00 | — | 0.00 | |
P/Operating CF |
(17.89) | (15.35) | — | (8.91) | |
P/B ratio |
5.84 | 6.74 | — | 5.32 | |
Price to Tangible BV |
0.00 | 0.00 | — | 0.00 | |
EV/Sales |
48.34 | 38.95 | — | 12.78 | |
EV/EBITDA |
0.00 | 0.00 | — | 0.00 | |
EV/Operating CF |
(2.49) | (2.16) | — | (1.09) | |
EV/FCF |
(2.46) | (2.13) | — | (1.08) | |
Quick Ratio |
0.98 | 0.82 | 0.89 | 0.80 | |
Current Ratio |
1.02 | 0.87 | 0.93 | 0.85 | |
Net Debt/EBITDA |
6.23 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.11 | 0.00 | 0.00 | |
Asset Turnover |
0.02 | 0.04 | 0.00 | 0.04 | |
Operating CF/Net income |
0.96 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
(0.13) | — | (0.42) | — | |
Interest Coverage |
(351.49) | (227.64) | — | (166.23) | |
Research and Development Expense of Revenue |
3,008.27% | 1,049.47% | — | 303.73% | |
Selling, General and Administrative Expense of Revenue |
1,165.84% | 373.00% | — | 108.57% | |
Intangible Assets out of Total Assets |
0.33 | 0.00 | 0.34 | 0.36 | |
Share Based Compensation of Revenue |
207.23% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
(0.05) | (0.12) | — | (0.21) | |
Graham Number |
0.00 | 0.00 | — | 0.00 | |
Earnings Yield |
(26.75%) | (29.82%) | — | (27.87%) | |
Free Cash Flow Yield |
(26.76%) | (31.20%) | — | (47.45%) | |
Revenue per Share |
0.00 | 0.01 | — | 0.06 | |
Operating CF per Share |
(0.18) | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.18) | 0.00 | 0.00 | 0.00 | |
Cash per Share |
1.10 | 0.97 | 0.00 | 1.35 | |
Shareholders Equity per Share |
0.54 | 0.41 | 0.00 | 0.49 | |
Interest Debt per Share |
0.00 | 0.00 | — | 0.00 | |
Book value per Share |
0.54 | 0.41 | 0.00 | 0.49 | |
Free Cash Flow |
(17.78) | — | (20.34) | — | |
Working Capital |
2.45 | (15.56) | (8.65) | (18.54) | |
Capital Expenditures |
(0.10) | — | (0.54) | — | |
Net Current Asset Value |
(15.26) | (32.97) | (27.62) | (36.52) | |
EV/EBIT |
0.00 | 0.00 | — | 0.00 | |
Capex to Sales |
0.21 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | — | 0.00 | |
| Other line items | |||||
Average Receivables |
1.22 | 1.92 | 9.48 | 3.39 | |
Average Payables |
2.76 | 2.17 | 2.61 | 1.49 | |
Average Assets |
224.24 | 117.40 | 212.56 | 201.00 | |
Average Common Equity |
90.85 | 72.85 | 67.55 | 55.60 |
Columns are period end dates · fundamentals updated 6 Nov 2026